With an increase in digital technology being utilized as a strategic differentiator and business enabler in pharma, where is talent coming from?
In pharma, digital is increasingly seen as a strategic differentiator and business enabler. But who, exactly, is pulling the digital strings within pharma companies, and where is talent coming from?
In 2019 we met with digital and technology leaders at 10 of the largest global pharma companies to understand the talent, leadership, and regional strategies behind the efforts to advance their organizations’ digital capabilities.
Starting with the “who," it is clear that digital leaders have disruption in their DNA. In pharma, these leaders have become more than technology specialists, and this is clear based on the emergence of three leadership archetypes that span the range from a digital focus on one side and a technology and engineering focus on the other:
Despite the diversity of mandates, leaders within each of these archetypes must also possess key “game-changing” qualities:
Visionary: Where previously a top-notch technologist or IT professional would have fit the bill, today’s pharma digital leader must also be a visionary with an informed and bold perspective on the future.
Commercially astute: The next generation of digital leaders in Pharma must be able to translate digital innovation into revenue and shareholder value.
Change agent: Pharma's new digital leader must be capable of leveraging the excitement of change and transforming culture and mindset, all the while managing unpredictability and successfully ushering the organization on its path forward.
This skillset is a departure from the profile of the typical pharma CIO or IT leader of the past. Today’s leaders are driving sweeping cultural and structural changes, and the Pharma organizations most open to these transformations are the ones finding the most success.
Pharma’s digital leaders of tomorrow have a wide remit, but it is also the case that-despite their mix of domain knowledge, business acumen, and change-management prowess-they cannot singlehandedly usher in a pharma organization’s digital transformation. As pharma companies move aggressively on their overall digital strategy, their data, technology, and digital functional capabilities are becoming increasingly intertwined.
Click to enlarge
While the Chief Digital Officer, Chief Digital and Information Officer, or whoever sits at the digital C-suite desk defines and leads the digital strategy, enterprise-wide transformation requires the commitment of many other leaders. In particular, the heads of the technology, data, and digital functions must also be visionary. The ability of these leaders to also successfully interface with their counterparts is key to driving a coordinated change effort in the organization. Based on our conversations, elevating these positions to the ExCo level is how successful pharma companies are facilitating that process.
So where is this talent coming from? The answers speak to both geography and industry. While the emergence of disruptive technologies is prevalent globally, there are clear, region-specific pockets of expertise emerging. The U.S. appears to be a geographical hotspot when it comes to digital leadership talent development. This is due, at least in part, to a regulatory environment that allows broad use of customer data.
Global companies are re-orienting their location strategies toward building digital hubs in regions where top talent already resides, and this means a shift toward the U.S. We spoke with an executive at a leading big pharma company who said that their company is shifting its regional balance in technology and digital leadership. Until recently, 70% of the technology and digital workforce was located in Europe. The new strategy will transition 60% of the digital workforce to the U.S.
The question of “where” also pertains to the world of industrial sectors. Specifically, pharma is looking outside the sector to hire talent skilled in building, implementing and leveraging disruptive technologies. Only 25% of CDOs have an exclusively life sciences background. In this respect, pharma is in line with the strategic hiring practices of other sectors. For example, the transportation, retail, and hospitality sectors have each, over time, looked beyond their industries for talent as their commitment to digital innovation has grown.
Pharma companies have clearly begun their digital journeys. They need digital and technology leaders with the organizational, technological, and commercial acumen to light the way. Companies leading the digital charge are building organizational structures that nurture digital innovation and cultivating cultures that attract dynamic digital leaders.
Wolfgang Bauriedel is a consultant in leadership advisory and executive search firm Russell Reynolds Associates’ Technology Practice; Maneesh Dube is a consultant in Russell Reynolds Associates’ Technology Practice.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.